Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

##STR00001##

The present invention features agents for treating autoimmune diseases and other conditions characterized by pathological immune responses, and for preventing or reversing immune recognition of neoantigens associated with therapeutic proteins or gene therapy vectors.

The present invention features agents for treating autoimmune diseases and other conditions characterized by pathological immune responses, and for preventing or reversing immune recognition of neoantigens associated with therapeutic proteins or gene therapy vectors.

The present invention features agents for treating autoimmune diseases and other conditions characterized by pathological immune responses, and for preventing or reversing immune recognition of neoantigens associated with therapeutic proteins or gene therapy vectors.

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions. ##STR00001##

Compositions and devices comprising apomorphine or pharmaceutically acceptable salts are described. The compositions may comprise a solution of apomorphine, or a pharmaceutically acceptable salt thereof, and a propellant. The solution may be a non-aqueous solution or an aqueous solution comprising degassed water. Devices may be configured to deliver compositions in form of particles or droplets having a mass median aerodynamic diameter (MMAD) or volume median diameter (VMD) greater than 10 pm; and/or a fine particle fraction (FRF) less than 30%.

Provided, inter alia, are methods and compositions for treating FTO-mediated cancer.

Provided, inter alia, are methods and compositions for treating FTO-mediated cancer.

The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of Chemical Formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating or treating cognitive disorder or for improving enhancing cognitive function.